Canal-U

Mon compte

Résultats de recherche

Nombre de programmes trouvés : 14437
Label UNT Conférences

le (10m40s)

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Non-inferiority, superiority, or both? Operationalizing the FDA guidance (debates).

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : <br>Non-inferiority, superiority, or both? Operationalizing the FDA guidance (debates).Speaker: Marc PFEFFER, Boston, USADiscussant: Stuart POCOCK, London, GBRRegulatory viewpoint: Kristina DUNDER, EMEA, SWEAbstract : Non-inferiority, superiority, or both? Operationalizing the FDA guidance (debates).L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.Conférence enregistrée : 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Diabetes clinical trials : helped or hindered by the current shift in regulatory requirements? Glycaemic control is an inadequate surrogate marker of cardiovascular event reduction in patients ...
Voir la vidéo
Label UNT Conférences

le (46m31s)

Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Save life and save cost with ivabradine.

Title : Cardiovascular Clinical Trialists (CVCT) Forum - Paris 2012 : Save life and save cost with ivabradine.Speaker: Martin COWIE, London, GBRAbstract :  Clinical evidence suggests that an elevated resting heart rate is a risk factor for mortality and morbidity in heart failure (HF) patients. SHIfT examined the effect of adding ivabradine, a heart rate lowering therapy, to optimised standard therapy in HF patients with a heart rate ?70bpm, in sinus rhythm and with left ventricular systolic dysfunction.1 Ivabradine plus standard therapy significantly reduced the risk of a primary composite event (CV death and hospitalisation for worsening HF) versus standard therapy (hazard ...
Voir la vidéo
Label UNT Conférences

le (26m40s)

Cardiovascular Clinical Trialists (CVCT) Forum – Lipid lowering agents. Now, we have an option! (SHARP, 4D, AURORA)

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Lipid lowering agents. Now, we have an option! (SHARP, 4D, AURORA)Speaker: Colin BAIGENT, Oxford, GBRAbstract : Lipid lowering agents. Now, we have an option! (SHARP, 4D, AURORA)L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.Conférence enregistrée : 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Cardiovascular prevention in chronic kidney disease. New therapeutic options and future opportunities- Cardiovascular events are 10 to 20 fold higher in CKD patients. Heart failure is the main cardiovascular complication that occurs in renal patients. Nearly all ...
Voir la vidéo
Label UNT Conférences

le (20m6s)

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients.

Title: Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients.Speakers: Chris MIX, Amgen, USA - David WHEELER, London, GBRDiscussant: Ziad MASSY, Boulogne-Billancourt, FRAAbstract : EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients.L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.Conférence enregistrée : 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Cardiovascular prevention in chronic kidney disease. New therapeutic options and future opportunities- Cardiovascular events are 10 to 20 fold higher in CKD patients. Heart failure is the main cardiovascular complication that occurs ...
Voir la vidéo
Label UNT Conférences

le (10m18s)

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients

Title : Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patientsSpeakers: Chris MIX, Amgen, USA - David WHEELER, London, GBRDiscussant: Ziad MASSY, Boulogne-Billancourt, FRAAbstract : EVOLVE: A major cardiovascular outcomes trial in hemodialysis patientsL’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.Conférence enregistrée : 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Cardiovascular prevention in chronic kidney disease. New therapeutic options and future opportunities- Cardiovascular events are 10 to 20 fold higher in CKD patients. Heart failure is the main cardiovascular complication that occurs ...
Voir la vidéo
Label UNT Conférences

le (9m25s)

Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients (debates).

Title : Cardiovascular Clinical Trialists (CVCT) Forum – EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients (debates).Speakers: Chris MIX, Amgen, USA - David WHEELER, London, GBRDiscussant: Ziad MASSY, Boulogne-Billancourt, FRA.Abstract : EVOLVE: A major cardiovascular outcomes trial in hemodialysis patients (debates).L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.Conférence enregistrée : 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Cardiovascular prevention in chronic kidney disease. New therapeutic options and future opportunities- Cardiovascular events are 10 to 20 fold higher in CKD patients. Heart failure is the main cardiovascular complication ...
Voir la vidéo
Label UNT Conférences

le (22m32s)

Cardiovascular Clinical Trialists (CVCT) Forum – RAAS inhibitors and Mineralocorticoid receptor antagonists (FOSIDIAL, ALCHEMIST)

Title : Cardiovascular Clinical Trialists (CVCT) Forum – RAAS inhibitors and Mineralocorticoid receptor antagonists (FOSIDIAL, ALCHEMIST)Speaker: Patrick ROSSIGNOL, Nancy, FRAAbstract : RAAS inhibitors and Mineralocorticoid receptor antagonists (FOSIDIAL, ALCHEMIST)L’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.Conférence enregistrée : 9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Cardiovascular prevention in chronic kidney disease. New therapeutic options and future opportunities- Cardiovascular events are 10 to 20 fold higher in CKD patients. Heart failure is the main cardiovascular complication that occurs in renal patients. Nearly all CV prevention and heart failure trials ...
Voir la vidéo
Label UNT Conférences

le (15m37s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : How should diagnostic/prognostic markers be studied?Speaker: Jim JANUZZI, Boston, USADiscussant: James SNIDER, Critical Diagnostics, USAAbstract : How should Diagnostic and Prognostic Markers Be Studied? The measurement of biomarkers for diagnosis and prognosis in heart disease has changed the fundamental way that patients are evaluated, and has led to a literal explosion of studies exploring both novel applications of established biomarkers as well as the discovery of newer biological markers. With the rise in interest in novel biomarkers has come a clear heterogeneity in the approach with which these potentially important tests ...
Voir la vidéo
Label UNT Conférences

le (11m50s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Autonomic modulation therapy for heart failure: Preclinical data and ongoing trials

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Autonomic modulation therapy for heart failure: Preclinical data and ongoing trialsSpeaker: Faiez ZANNAD, Nancy, FRADiscussant: Gaetano DE FERRARI, Pavia, ITAAbstract : Autonomic modulation therapy for heart failure: Preclinical data and ongoing trialsL’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 HYPERTENSION TRIALIST WORKSHOP: AUTONOMIC MODULATION THERAPYChairpersons: George BAKRIS, Chicago, USA - Sverre E. KJELDSEN, Oslo, NORResistant hypertension is usually defined as uncontrolled hypertension despite the intake of at least 3 antihypertensive drugs ...
Voir la vidéo
Label UNT Conférences

le (19m43s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursement

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursementInvestigator viewpoint: George BAKRIS, Chicago, USA - Ileana PIÑA, New York, USARegulatory viewpoint: Andrew FARB, FDA, USAIndustry viewpoint: Rob KIEVAL, CVRx, USA - Kenneth STEIN, Boston Scientific, USAAbstract : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursementL’auteur n’a pas transmis de conflit ...
Voir la vidéo

 
FMSH
 
Facebook Twitter Google+
Mon Compte